Epilepsy

Neurology News Network for the week ending July 23, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 22, 2022.

Joseph E. Sullivan, MD, leads a discussion on treatment options for the management of patients with LGS and considers the impact of treatment on quality of life.

Kelly Knupp, MD, shares her perspective of a provider journey of a new patient with LGS and goal setting to manage the disease.

Findings showed between a 2.4- to 5-fold increased risk of autism spectrum disorder and intellectual disability in children with prenatal exposure to valproate, and similar findings for those exposed to topiramate.

Over a year treatment period, patients maintained their subscale scores assessing medication effects, energy and fatigue, and cognition, all of which might be expected to be sensitive to a new treatment.

Previously used to treat conditions such as temporal lobe epilepsy and focal impaired awareness, the FDA approved a new oral suspension of zonisamide, an antiseizure medication on the market for over 2 decades.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 15, 2022.

Tracy Dixon-Salazar, PhD, reflects on her daughter’s journey to diagnosis of Lennox-Gastaut Syndrome and the impact of the disease on caregivers.

Tracy Dixon-Salazar, PhD, and Kelly Knupp, MD, emphasize key identifiers for the diagnosis of Lennox-Gastaut Syndrome and challenges in managing seizures in these patients.

The presence of concurrent psychogenic nonepileptic seizures increased the odds of hospitalization for first suicide by 152% compared with epilepsy alone.

Get caught up on some of the latest news in epilepsy and seizure disorders, with data updates and expert insights, all in one place from the NeurologyLive® team.

Here's what is coming soon to NeurologyLive®.

Of the patients with drug-resistant epilepsy in the cohort, 54% had status epilepticus during their acute admission, and 2 of 3 patients with NORSE ended up developing drug-resistant epilepsy at 12 months.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 8, 2022.

Kelly Knupp, MD, provides an overview of Lennox-Gastaut Syndrome (LGS).

Joseph E. Sullivan, MD, and Kelly Knupp, MD, share strategies for managing patients who have suboptimal seizure control with medications.

Expert clinicians offer their insight on the sleep disorder landscape, the state of mental health in pediatric migraine, an inaugural movement disorders congress, a novel stroke rehabilitation tool, and psychedelics in cluster headache.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Neurology News Network for the week ending July 2, 2022. [WATCH TIME: 4 minutes]